Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
about
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kgEnzyme replacement therapy for Anderson-Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseSafety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseaseInterconversion of the Specificities of Human Lysosomal Enzymes Associated with Fabry and Schindler DiseasesA phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)Agalsidase alfa: a review of its use in the management of Fabry diseaseReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseDevelopment of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase A protein levels in serum and plasmaSubstrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseFabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Effectiveness of enzyme replacement therapy in Fabry disease: Long term experience in Argentina.Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.Stroke and Fabry disease.A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.Enzyme replacement therapy for Fabry disease: some answers but more questionsToward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group.Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsUpdate on role of agalsidase alfa in management of Fabry disease.Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyCarboxyl-terminal truncations alter the activity of the human α-galactosidase AConsequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities.The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.Cellular and tissue distribution of intravenously administered agalsidase alfa.Pharmacological chaperone therapy for Fabry diseaseInnate and Adaptive Immune Response in Fabry DiseaseA Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients.Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry DiseaseEffect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceAgalsidase benefits renal histology in young patients with Fabry disease.Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysisRecommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease
P2860
Q21004071-1D4C40B5-3801-42FA-97D8-F911C7A2B4F0Q24200877-99E8F9A4-333B-4241-B710-FEB762044DA2Q24235483-BC47B25A-8876-4B70-A762-ECA8A8F9D2B9Q24650910-B0A4166B-00E2-4C6E-BE98-0C1CFEE2FD19Q26471010-BB1F66C9-476F-4117-941D-15AE8CF0087FQ27661323-E2997D51-40AD-4147-840D-F932F2A6147EQ28258072-3DCEC98B-AD18-4CC2-9D48-567F15C46BB5Q28274194-FE817683-2443-479A-8444-CE3A1C7D7C37Q28477142-D71A4C8E-4E34-44F6-A1FF-CBA08B22D91DQ28535053-FDCB47B1-D8B1-473F-BE1A-5E38EC4035A4Q28748170-F4D88130-75FD-4AA7-814B-A3215C859B98Q33645550-5EF2DCDD-DB78-474D-ADAF-329225AEA162Q33652370-9357C242-EBBA-4583-8E21-E4DC386253E8Q33776219-2FE48CFE-7701-4B74-963B-5AE019FBC310Q34061632-F92D50E0-5CDE-408B-A7D0-A518587E5090Q34159448-BD3AB806-1C7D-4FDB-A650-A67285940AFDQ34703815-14E9520F-294B-47C5-BA12-3D5ABCCB69D9Q34714417-D2089FFE-78E3-4979-946B-1DA062B27C6AQ34734676-995F7F94-8CE4-4A8E-8E54-983ACC4B801DQ34805283-C07114B6-7097-4B55-BD5F-F92BDB9F8841Q34883178-A8946698-949C-4BEE-B63C-DB1A8CDA6B58Q34945403-BF2941CB-3E5C-4840-A481-778082352411Q35125851-44430624-38BB-446D-A41C-33A71ABAE1F9Q35560027-B11A684C-646B-4144-89F1-E109988EBDE7Q35587768-E5E5E215-43BB-4BA5-8156-6F6C3B25BB3FQ35635580-A982703E-F2FB-4FDE-BFB3-1D00DA4DFEA4Q35692435-1A95FB2E-1C33-4F6B-9D17-895B0CAF0EF7Q35728693-E43A0E7D-741A-4D14-93DD-CA21B5776B82Q35755438-4560424F-B882-43D6-8E31-D65494CD6BF5Q35800976-FEB3E667-EF82-4C02-BB21-1AE340647B63Q35900813-7576540A-FC72-48D9-8D7E-D497AFCE53C5Q35945846-6AD46D0E-C203-4C43-A336-B4D67471CCC8Q35994824-A34ECB9B-AE31-4F0A-9659-4638613A4537Q36025702-7D79E925-4867-4900-9AB5-96BB6CF16F8EQ36433306-0965C01E-49B8-4BC8-A38D-7AC22770DDD8Q36509288-232CC54A-64A9-42F9-BB19-A36EA4BAE27FQ36571559-FF9A2ABC-0860-4FED-813E-19D469AF0469Q36590963-F5FCB09E-8407-4936-BCB4-45A6CE0B077EQ36767452-B250F4AC-0B0E-43B5-BD27-161CF153D411Q36808226-CA00C56F-9A61-4F07-8B5E-77E504BBD85A
P2860
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Long-term therapy with agalsid ...... on in a home infusion setting.
@en
Long-term therapy with agalsid ...... on in a home infusion setting.
@nl
type
label
Long-term therapy with agalsid ...... on in a home infusion setting.
@en
Long-term therapy with agalsid ...... on in a home infusion setting.
@nl
prefLabel
Long-term therapy with agalsid ...... on in a home infusion setting.
@en
Long-term therapy with agalsid ...... on in a home infusion setting.
@nl
P2093
P2860
P356
P1476
Long-term therapy with agalsid ...... on in a home infusion setting.
@en
P2093
John T Flaherty
Margaret Timmons
Raphael Schiffmann
Roscoe O Brady
P2860
P304
P356
10.1093/NDT/GFI152
P407
P50
P577
2005-10-04T00:00:00Z